Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RITUXIMAB Cause Suspected product quality issue? 10 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Suspected product quality issue have been filed in association with RITUXIMAB (Rituxan). This represents 0.0% of all adverse event reports for RITUXIMAB.

10
Reports of Suspected product quality issue with RITUXIMAB
0.0%
of all RITUXIMAB reports
0
Deaths
10
Hospitalizations

How Dangerous Is Suspected product quality issue From RITUXIMAB?

Of the 10 reports, 10 (100.0%) required hospitalization, and 10 (100.0%) were considered life-threatening.

Is Suspected product quality issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RITUXIMAB. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does RITUXIMAB Cause?

Off label use (39,751) Drug ineffective (32,186) Rheumatoid arthritis (19,850) Pain (16,675) Fatigue (15,602) Arthralgia (12,529) Rash (12,102) Drug intolerance (11,876) Infusion related reaction (11,871) Joint swelling (11,170)

What Other Drugs Cause Suspected product quality issue?

AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (64) LEVOTHYROXINE (37) HUMAN IMMUNOGLOBULIN G (32) ESTRADIOL (30) ONABOTULINUMTOXINA (30) SODIUM (30) CLONAZEPAM (29) AFLIBERCEPT (27) INSULIN GLARGINE (27) IOPROMIDE (25)

Which RITUXIMAB Alternatives Have Lower Suspected product quality issue Risk?

RITUXIMAB vs RITUXIMAB-ABBS RITUXIMAB vs RITUXIMAB-ARRX RITUXIMAB vs RITUXIMAB-PVVR RITUXIMAB vs RIVAROXABAN RITUXIMAB vs RIVASTIGMINE

Related Pages

RITUXIMAB Full Profile All Suspected product quality issue Reports All Drugs Causing Suspected product quality issue RITUXIMAB Demographics